Early in 1995, for example, the National Heart, Lung, and Blood Institute in the United States announced that the drug hydroxyurea reduced by half the frequency of painful crises in sickle-cell patients.
Tako je, naprimjer, Nacionalni institut za srce, pluća i krv u Sjedinjenim Državama početkom 1995. objavio da lijek hydroxyurea upola smanjuje učestalost bolnih grčeva kod oboljelih od anemije srpastih stanica.jw2019 jw2019